Summary COVID-19, caused by SARS-CoV-2, is characterised by a broad spectrum of
symptom severity that requires varying amounts of care according to the different stages of …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) belongs to the group of
Betacoronaviruses. The SARS-CoV-2 is closely related to SARS-CoV-1 and probably …

Background Multiple early reports of patients admitted to hospital with COVID-19 showed
that patients with chronic respiratory disease were significantly under-represented in these …

Background A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …

Background Studies of patients admitted to hospital with COVID-19 have found varying
mortality outcomes associated with underlying respiratory conditions and inhaled …

Objectives To investigate the risk factors contributing to severity on admission. Additionally,
risk factors of worst severity and fatality were studied. Moreover, factors were compared …

It has been reported that corticosteroid therapy was effective in the management of severe
acute respiratory syndrome (SARS) and the Middle East Respiratory Syndrome (MERS) …

Coronavirus disease-2019 (COVID-19) is caused by coronavirus-2 (SARS-CoV-2) and has
produced a global pandemic. As of 22 June 2021, 178 million people have been affected …

The novel coronavirus disease‐2019 (COVID‐19), caused by the pathogen severe acute
respiratory syndrome‐CoV‐2, is causing a global pandemic, with over 26.9 million cases …

To face the COVID-19 pandemic, prophylactic vaccines have been developed in record
time, but vaccine coverage is still limited, accessibility is not equitable worldwide, and the …